Postradiation Metabolic Tumor Volume Predicts Outcome in Head-and-Neck Cancer
Purpose To explore the prognostic value of metabolic tumor volume measured on postradiation18 F-fluorodeoxyglucose positron emission tomography (PET) imaging in patients with head-and-neck cancer. Methods and Materials Forty-seven patients with head-and-neck cancer who received pretreatment and post...
Gespeichert in:
| Veröffentlicht in: | International journal of radiation oncology, biology, physics biology, physics, 2011-06, Vol.80 (2), p.514-521 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 521 |
|---|---|
| container_issue | 2 |
| container_start_page | 514 |
| container_title | International journal of radiation oncology, biology, physics |
| container_volume | 80 |
| creator | Murphy, James D., M.D La, Trang H., M.D Chu, Karen, M.D Quon, Andrew, M.D Fischbein, Nancy J., M.D Maxim, Peter G., Ph.D Graves, Edward E., Ph.D Loo, Billy W., M.D., Ph.D Le, Quynh-Thu, M.D |
| description | Purpose To explore the prognostic value of metabolic tumor volume measured on postradiation18 F-fluorodeoxyglucose positron emission tomography (PET) imaging in patients with head-and-neck cancer. Methods and Materials Forty-seven patients with head-and-neck cancer who received pretreatment and posttreatment PET/computed tomography (CT) imaging along with definitive chemoradiotherapy were included in this study. The PET/CT parameters evaluated include the maximum standardized uptake value, metabolic tumor volume (MTV2.0 –MTV4.0 ; where MTV2.0 refers to the volume above a standardized uptake value threshold of 2.0), and integrated tumor volume. Kaplan-Meier and Cox regression models were used to test for association between PET endpoints and disease-free survival and overall survival. Results Multiple postradiation PET endpoints correlated significantly with outcome; however, the most robust predictor of disease progression and death was MTV2.0 . An increase in MTV2.0 of 21cm3 (difference between 75th and 25th percentiles) was associated with an increased risk of disease progression (hazard ratio [HR] = 2.5, p = 0.0001) and death (HR = 2.0, p = 0.003). In patients with nonnasopharyngeal carcinoma histology ( n = 34), MTV2.0 |
| doi_str_mv | 10.1016/j.ijrobp.2010.01.057 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_osti_</sourceid><recordid>TN_cdi_osti_scitechconnect_21491773</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0360301610002312</els_id><sourcerecordid>1687663122</sourcerecordid><originalsourceid>FETCH-LOGICAL-c619t-2f81789e0ce961714c0dd726762fe38fac6bef304a7d4b1242b8de9f18e090433</originalsourceid><addsrcrecordid>eNqFkt9r1TAUgIMo7m76H4gURNhLr-ekvUn7IshFnbC5gVN8C2lyiuna5i5phf33pvSq4ItPgcN3fn05jL1A2CKgeNNtXRd8c9hySCHALezkI7bBStZ5sdt9f8w2UAjIiwSfsNMYOwBAlOVTdsJBlKKSsGFXNz5OQVunJ-fH7Iom3fjemex2HnzIvvl-Hii7CWSdmWJ2PU_Gp4AbswvSNtejzT-Tucv2ejQUnrEnre4jPT--Z-zrh_e3-4v88vrjp_27y9wIrKectxXKqiYwVAuUWBqwVnIhBW-pqFptRENtAaWWtmyQl7ypLNUtVgQ1lEVxxl6tddPwTkXjJjI_jB9HMpPiWNYo5UKdr9Qh-PuZ4qQGFw31vR7Jz1FhUiBEgZwntFxRE3yMgVp1CG7Q4UEhqEW36tSqWy26FaBKulPay2OHuRnI_kn67TcBr4-Ajkb3bUiaXPzLlVjV1W4Z9e3KUbL201FYlqKk1Lqw7GS9-98k_xYwvRtd6nlHDxQ7P4cx_YhCFbkC9WU5jeUyMB0FTwqKX_4tsqg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1687663122</pqid></control><display><type>article</type><title>Postradiation Metabolic Tumor Volume Predicts Outcome in Head-and-Neck Cancer</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Murphy, James D., M.D ; La, Trang H., M.D ; Chu, Karen, M.D ; Quon, Andrew, M.D ; Fischbein, Nancy J., M.D ; Maxim, Peter G., Ph.D ; Graves, Edward E., Ph.D ; Loo, Billy W., M.D., Ph.D ; Le, Quynh-Thu, M.D</creator><creatorcontrib>Murphy, James D., M.D ; La, Trang H., M.D ; Chu, Karen, M.D ; Quon, Andrew, M.D ; Fischbein, Nancy J., M.D ; Maxim, Peter G., Ph.D ; Graves, Edward E., Ph.D ; Loo, Billy W., M.D., Ph.D ; Le, Quynh-Thu, M.D</creatorcontrib><description>Purpose To explore the prognostic value of metabolic tumor volume measured on postradiation18 F-fluorodeoxyglucose positron emission tomography (PET) imaging in patients with head-and-neck cancer. Methods and Materials Forty-seven patients with head-and-neck cancer who received pretreatment and posttreatment PET/computed tomography (CT) imaging along with definitive chemoradiotherapy were included in this study. The PET/CT parameters evaluated include the maximum standardized uptake value, metabolic tumor volume (MTV2.0 –MTV4.0 ; where MTV2.0 refers to the volume above a standardized uptake value threshold of 2.0), and integrated tumor volume. Kaplan-Meier and Cox regression models were used to test for association between PET endpoints and disease-free survival and overall survival. Results Multiple postradiation PET endpoints correlated significantly with outcome; however, the most robust predictor of disease progression and death was MTV2.0 . An increase in MTV2.0 of 21cm3 (difference between 75th and 25th percentiles) was associated with an increased risk of disease progression (hazard ratio [HR] = 2.5, p = 0.0001) and death (HR = 2.0, p = 0.003). In patients with nonnasopharyngeal carcinoma histology ( n = 34), MTV2.0 <18 cm3 and MTV2.0 ≥18 cm3 yielded 2-year disease-free survival rates of 100% and 63%, respectively ( p = 0.006) and 2-year overall survival rates of 100% and 81%, respectively ( p = 0.009). There was no correlation between MTV2.0 and disease-free survival or overall survival with nasopharyngeal carcinoma histology ( n = 13). On multivariate analysis, only postradiation MTV2.0 was predictive of disease-free survival (HR = 2.47, p = 0.0001) and overall survival (HR = 1.98, p = 0.003). Conclusions Postradiation metabolic tumor volume is an adverse prognostic factor in head-and-neck cancer. Biomarkers such as MTV are important for risk stratification and will be valuable in the future with risk-adapted therapies.</description><identifier>ISSN: 0360-3016</identifier><identifier>EISSN: 1879-355X</identifier><identifier>DOI: 10.1016/j.ijrobp.2010.01.057</identifier><identifier>PMID: 20646870</identifier><identifier>CODEN: IOBPD3</identifier><language>eng</language><publisher>New York, NY: Elsevier Inc</publisher><subject>Adolescent ; Adult ; Aged ; Aged, 80 and over ; ANTIMETABOLITES ; BETA DECAY RADIOISOTOPES ; BETA-PLUS DECAY RADIOISOTOPES ; Biological and medical sciences ; BODY ; Carcinoma, Squamous Cell - diagnostic imaging ; Carcinoma, Squamous Cell - drug therapy ; Carcinoma, Squamous Cell - metabolism ; Carcinoma, Squamous Cell - radiotherapy ; CARCINOMAS ; Combined Modality Therapy - methods ; COMBINED THERAPY ; COMPUTERIZED TOMOGRAPHY ; DIAGNOSTIC TECHNIQUES ; Disease-Free Survival ; DISEASES ; DRUGS ; EMISSION COMPUTED TOMOGRAPHY ; Female ; FLUORINE 18 ; FLUORINE ISOTOPES ; FLUORODEOXYGLUCOSE ; Fluorodeoxyglucose F18 - pharmacokinetics ; HEAD ; Head and Neck Neoplasms - diagnostic imaging ; Head and Neck Neoplasms - drug therapy ; Head and Neck Neoplasms - metabolism ; Head and Neck Neoplasms - radiotherapy ; Head-and-neck cancer ; Hematology, Oncology and Palliative Medicine ; HOURS LIVING RADIOISOTOPES ; Humans ; ISOMERIC TRANSITION ISOTOPES ; ISOTOPES ; LIGHT NUCLEI ; Male ; Medical sciences ; MEDICINE ; Metabolic tumor volume ; Middle Aged ; NANOSECONDS LIVING RADIOISOTOPES ; NECK ; NEOPLASMS ; NUCLEI ; ODD-ODD NUCLEI ; Otorhinolaryngology (head neck, general aspects and miscellaneous) ; Otorhinolaryngology. Stomatology ; POSITRON COMPUTED TOMOGRAPHY ; Positron emission tomography ; Positron-Emission Tomography - methods ; Prognosis ; Proportional Hazards Models ; RADIOISOTOPES ; Radiology ; RADIOLOGY AND NUCLEAR MEDICINE ; Radiopharmaceuticals - pharmacokinetics ; Retrospective Studies ; Survival Rate ; THERAPY ; TOMOGRAPHY ; Tomography, X-Ray Computed - methods ; Treatment Outcome ; Tumor Burden ; Tumors ; VOLUME ; Young Adult</subject><ispartof>International journal of radiation oncology, biology, physics, 2011-06, Vol.80 (2), p.514-521</ispartof><rights>Elsevier Inc.</rights><rights>2011 Elsevier Inc.</rights><rights>2015 INIST-CNRS</rights><rights>Copyright © 2011 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c619t-2f81789e0ce961714c0dd726762fe38fac6bef304a7d4b1242b8de9f18e090433</citedby><cites>FETCH-LOGICAL-c619t-2f81789e0ce961714c0dd726762fe38fac6bef304a7d4b1242b8de9f18e090433</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0360301610002312$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,776,780,881,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=24189853$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20646870$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://www.osti.gov/biblio/21491773$$D View this record in Osti.gov$$Hfree_for_read</backlink></links><search><creatorcontrib>Murphy, James D., M.D</creatorcontrib><creatorcontrib>La, Trang H., M.D</creatorcontrib><creatorcontrib>Chu, Karen, M.D</creatorcontrib><creatorcontrib>Quon, Andrew, M.D</creatorcontrib><creatorcontrib>Fischbein, Nancy J., M.D</creatorcontrib><creatorcontrib>Maxim, Peter G., Ph.D</creatorcontrib><creatorcontrib>Graves, Edward E., Ph.D</creatorcontrib><creatorcontrib>Loo, Billy W., M.D., Ph.D</creatorcontrib><creatorcontrib>Le, Quynh-Thu, M.D</creatorcontrib><title>Postradiation Metabolic Tumor Volume Predicts Outcome in Head-and-Neck Cancer</title><title>International journal of radiation oncology, biology, physics</title><addtitle>Int J Radiat Oncol Biol Phys</addtitle><description>Purpose To explore the prognostic value of metabolic tumor volume measured on postradiation18 F-fluorodeoxyglucose positron emission tomography (PET) imaging in patients with head-and-neck cancer. Methods and Materials Forty-seven patients with head-and-neck cancer who received pretreatment and posttreatment PET/computed tomography (CT) imaging along with definitive chemoradiotherapy were included in this study. The PET/CT parameters evaluated include the maximum standardized uptake value, metabolic tumor volume (MTV2.0 –MTV4.0 ; where MTV2.0 refers to the volume above a standardized uptake value threshold of 2.0), and integrated tumor volume. Kaplan-Meier and Cox regression models were used to test for association between PET endpoints and disease-free survival and overall survival. Results Multiple postradiation PET endpoints correlated significantly with outcome; however, the most robust predictor of disease progression and death was MTV2.0 . An increase in MTV2.0 of 21cm3 (difference between 75th and 25th percentiles) was associated with an increased risk of disease progression (hazard ratio [HR] = 2.5, p = 0.0001) and death (HR = 2.0, p = 0.003). In patients with nonnasopharyngeal carcinoma histology ( n = 34), MTV2.0 <18 cm3 and MTV2.0 ≥18 cm3 yielded 2-year disease-free survival rates of 100% and 63%, respectively ( p = 0.006) and 2-year overall survival rates of 100% and 81%, respectively ( p = 0.009). There was no correlation between MTV2.0 and disease-free survival or overall survival with nasopharyngeal carcinoma histology ( n = 13). On multivariate analysis, only postradiation MTV2.0 was predictive of disease-free survival (HR = 2.47, p = 0.0001) and overall survival (HR = 1.98, p = 0.003). Conclusions Postradiation metabolic tumor volume is an adverse prognostic factor in head-and-neck cancer. Biomarkers such as MTV are important for risk stratification and will be valuable in the future with risk-adapted therapies.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>ANTIMETABOLITES</subject><subject>BETA DECAY RADIOISOTOPES</subject><subject>BETA-PLUS DECAY RADIOISOTOPES</subject><subject>Biological and medical sciences</subject><subject>BODY</subject><subject>Carcinoma, Squamous Cell - diagnostic imaging</subject><subject>Carcinoma, Squamous Cell - drug therapy</subject><subject>Carcinoma, Squamous Cell - metabolism</subject><subject>Carcinoma, Squamous Cell - radiotherapy</subject><subject>CARCINOMAS</subject><subject>Combined Modality Therapy - methods</subject><subject>COMBINED THERAPY</subject><subject>COMPUTERIZED TOMOGRAPHY</subject><subject>DIAGNOSTIC TECHNIQUES</subject><subject>Disease-Free Survival</subject><subject>DISEASES</subject><subject>DRUGS</subject><subject>EMISSION COMPUTED TOMOGRAPHY</subject><subject>Female</subject><subject>FLUORINE 18</subject><subject>FLUORINE ISOTOPES</subject><subject>FLUORODEOXYGLUCOSE</subject><subject>Fluorodeoxyglucose F18 - pharmacokinetics</subject><subject>HEAD</subject><subject>Head and Neck Neoplasms - diagnostic imaging</subject><subject>Head and Neck Neoplasms - drug therapy</subject><subject>Head and Neck Neoplasms - metabolism</subject><subject>Head and Neck Neoplasms - radiotherapy</subject><subject>Head-and-neck cancer</subject><subject>Hematology, Oncology and Palliative Medicine</subject><subject>HOURS LIVING RADIOISOTOPES</subject><subject>Humans</subject><subject>ISOMERIC TRANSITION ISOTOPES</subject><subject>ISOTOPES</subject><subject>LIGHT NUCLEI</subject><subject>Male</subject><subject>Medical sciences</subject><subject>MEDICINE</subject><subject>Metabolic tumor volume</subject><subject>Middle Aged</subject><subject>NANOSECONDS LIVING RADIOISOTOPES</subject><subject>NECK</subject><subject>NEOPLASMS</subject><subject>NUCLEI</subject><subject>ODD-ODD NUCLEI</subject><subject>Otorhinolaryngology (head neck, general aspects and miscellaneous)</subject><subject>Otorhinolaryngology. Stomatology</subject><subject>POSITRON COMPUTED TOMOGRAPHY</subject><subject>Positron emission tomography</subject><subject>Positron-Emission Tomography - methods</subject><subject>Prognosis</subject><subject>Proportional Hazards Models</subject><subject>RADIOISOTOPES</subject><subject>Radiology</subject><subject>RADIOLOGY AND NUCLEAR MEDICINE</subject><subject>Radiopharmaceuticals - pharmacokinetics</subject><subject>Retrospective Studies</subject><subject>Survival Rate</subject><subject>THERAPY</subject><subject>TOMOGRAPHY</subject><subject>Tomography, X-Ray Computed - methods</subject><subject>Treatment Outcome</subject><subject>Tumor Burden</subject><subject>Tumors</subject><subject>VOLUME</subject><subject>Young Adult</subject><issn>0360-3016</issn><issn>1879-355X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkt9r1TAUgIMo7m76H4gURNhLr-ekvUn7IshFnbC5gVN8C2lyiuna5i5phf33pvSq4ItPgcN3fn05jL1A2CKgeNNtXRd8c9hySCHALezkI7bBStZ5sdt9f8w2UAjIiwSfsNMYOwBAlOVTdsJBlKKSsGFXNz5OQVunJ-fH7Iom3fjemex2HnzIvvl-Hii7CWSdmWJ2PU_Gp4AbswvSNtejzT-Tucv2ejQUnrEnre4jPT--Z-zrh_e3-4v88vrjp_27y9wIrKectxXKqiYwVAuUWBqwVnIhBW-pqFptRENtAaWWtmyQl7ypLNUtVgQ1lEVxxl6tddPwTkXjJjI_jB9HMpPiWNYo5UKdr9Qh-PuZ4qQGFw31vR7Jz1FhUiBEgZwntFxRE3yMgVp1CG7Q4UEhqEW36tSqWy26FaBKulPay2OHuRnI_kn67TcBr4-Ajkb3bUiaXPzLlVjV1W4Z9e3KUbL201FYlqKk1Lqw7GS9-98k_xYwvRtd6nlHDxQ7P4cx_YhCFbkC9WU5jeUyMB0FTwqKX_4tsqg</recordid><startdate>20110601</startdate><enddate>20110601</enddate><creator>Murphy, James D., M.D</creator><creator>La, Trang H., M.D</creator><creator>Chu, Karen, M.D</creator><creator>Quon, Andrew, M.D</creator><creator>Fischbein, Nancy J., M.D</creator><creator>Maxim, Peter G., Ph.D</creator><creator>Graves, Edward E., Ph.D</creator><creator>Loo, Billy W., M.D., Ph.D</creator><creator>Le, Quynh-Thu, M.D</creator><general>Elsevier Inc</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7U7</scope><scope>C1K</scope><scope>OTOTI</scope></search><sort><creationdate>20110601</creationdate><title>Postradiation Metabolic Tumor Volume Predicts Outcome in Head-and-Neck Cancer</title><author>Murphy, James D., M.D ; La, Trang H., M.D ; Chu, Karen, M.D ; Quon, Andrew, M.D ; Fischbein, Nancy J., M.D ; Maxim, Peter G., Ph.D ; Graves, Edward E., Ph.D ; Loo, Billy W., M.D., Ph.D ; Le, Quynh-Thu, M.D</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c619t-2f81789e0ce961714c0dd726762fe38fac6bef304a7d4b1242b8de9f18e090433</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>ANTIMETABOLITES</topic><topic>BETA DECAY RADIOISOTOPES</topic><topic>BETA-PLUS DECAY RADIOISOTOPES</topic><topic>Biological and medical sciences</topic><topic>BODY</topic><topic>Carcinoma, Squamous Cell - diagnostic imaging</topic><topic>Carcinoma, Squamous Cell - drug therapy</topic><topic>Carcinoma, Squamous Cell - metabolism</topic><topic>Carcinoma, Squamous Cell - radiotherapy</topic><topic>CARCINOMAS</topic><topic>Combined Modality Therapy - methods</topic><topic>COMBINED THERAPY</topic><topic>COMPUTERIZED TOMOGRAPHY</topic><topic>DIAGNOSTIC TECHNIQUES</topic><topic>Disease-Free Survival</topic><topic>DISEASES</topic><topic>DRUGS</topic><topic>EMISSION COMPUTED TOMOGRAPHY</topic><topic>Female</topic><topic>FLUORINE 18</topic><topic>FLUORINE ISOTOPES</topic><topic>FLUORODEOXYGLUCOSE</topic><topic>Fluorodeoxyglucose F18 - pharmacokinetics</topic><topic>HEAD</topic><topic>Head and Neck Neoplasms - diagnostic imaging</topic><topic>Head and Neck Neoplasms - drug therapy</topic><topic>Head and Neck Neoplasms - metabolism</topic><topic>Head and Neck Neoplasms - radiotherapy</topic><topic>Head-and-neck cancer</topic><topic>Hematology, Oncology and Palliative Medicine</topic><topic>HOURS LIVING RADIOISOTOPES</topic><topic>Humans</topic><topic>ISOMERIC TRANSITION ISOTOPES</topic><topic>ISOTOPES</topic><topic>LIGHT NUCLEI</topic><topic>Male</topic><topic>Medical sciences</topic><topic>MEDICINE</topic><topic>Metabolic tumor volume</topic><topic>Middle Aged</topic><topic>NANOSECONDS LIVING RADIOISOTOPES</topic><topic>NECK</topic><topic>NEOPLASMS</topic><topic>NUCLEI</topic><topic>ODD-ODD NUCLEI</topic><topic>Otorhinolaryngology (head neck, general aspects and miscellaneous)</topic><topic>Otorhinolaryngology. Stomatology</topic><topic>POSITRON COMPUTED TOMOGRAPHY</topic><topic>Positron emission tomography</topic><topic>Positron-Emission Tomography - methods</topic><topic>Prognosis</topic><topic>Proportional Hazards Models</topic><topic>RADIOISOTOPES</topic><topic>Radiology</topic><topic>RADIOLOGY AND NUCLEAR MEDICINE</topic><topic>Radiopharmaceuticals - pharmacokinetics</topic><topic>Retrospective Studies</topic><topic>Survival Rate</topic><topic>THERAPY</topic><topic>TOMOGRAPHY</topic><topic>Tomography, X-Ray Computed - methods</topic><topic>Treatment Outcome</topic><topic>Tumor Burden</topic><topic>Tumors</topic><topic>VOLUME</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Murphy, James D., M.D</creatorcontrib><creatorcontrib>La, Trang H., M.D</creatorcontrib><creatorcontrib>Chu, Karen, M.D</creatorcontrib><creatorcontrib>Quon, Andrew, M.D</creatorcontrib><creatorcontrib>Fischbein, Nancy J., M.D</creatorcontrib><creatorcontrib>Maxim, Peter G., Ph.D</creatorcontrib><creatorcontrib>Graves, Edward E., Ph.D</creatorcontrib><creatorcontrib>Loo, Billy W., M.D., Ph.D</creatorcontrib><creatorcontrib>Le, Quynh-Thu, M.D</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>OSTI.GOV</collection><jtitle>International journal of radiation oncology, biology, physics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Murphy, James D., M.D</au><au>La, Trang H., M.D</au><au>Chu, Karen, M.D</au><au>Quon, Andrew, M.D</au><au>Fischbein, Nancy J., M.D</au><au>Maxim, Peter G., Ph.D</au><au>Graves, Edward E., Ph.D</au><au>Loo, Billy W., M.D., Ph.D</au><au>Le, Quynh-Thu, M.D</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Postradiation Metabolic Tumor Volume Predicts Outcome in Head-and-Neck Cancer</atitle><jtitle>International journal of radiation oncology, biology, physics</jtitle><addtitle>Int J Radiat Oncol Biol Phys</addtitle><date>2011-06-01</date><risdate>2011</risdate><volume>80</volume><issue>2</issue><spage>514</spage><epage>521</epage><pages>514-521</pages><issn>0360-3016</issn><eissn>1879-355X</eissn><coden>IOBPD3</coden><abstract>Purpose To explore the prognostic value of metabolic tumor volume measured on postradiation18 F-fluorodeoxyglucose positron emission tomography (PET) imaging in patients with head-and-neck cancer. Methods and Materials Forty-seven patients with head-and-neck cancer who received pretreatment and posttreatment PET/computed tomography (CT) imaging along with definitive chemoradiotherapy were included in this study. The PET/CT parameters evaluated include the maximum standardized uptake value, metabolic tumor volume (MTV2.0 –MTV4.0 ; where MTV2.0 refers to the volume above a standardized uptake value threshold of 2.0), and integrated tumor volume. Kaplan-Meier and Cox regression models were used to test for association between PET endpoints and disease-free survival and overall survival. Results Multiple postradiation PET endpoints correlated significantly with outcome; however, the most robust predictor of disease progression and death was MTV2.0 . An increase in MTV2.0 of 21cm3 (difference between 75th and 25th percentiles) was associated with an increased risk of disease progression (hazard ratio [HR] = 2.5, p = 0.0001) and death (HR = 2.0, p = 0.003). In patients with nonnasopharyngeal carcinoma histology ( n = 34), MTV2.0 <18 cm3 and MTV2.0 ≥18 cm3 yielded 2-year disease-free survival rates of 100% and 63%, respectively ( p = 0.006) and 2-year overall survival rates of 100% and 81%, respectively ( p = 0.009). There was no correlation between MTV2.0 and disease-free survival or overall survival with nasopharyngeal carcinoma histology ( n = 13). On multivariate analysis, only postradiation MTV2.0 was predictive of disease-free survival (HR = 2.47, p = 0.0001) and overall survival (HR = 1.98, p = 0.003). Conclusions Postradiation metabolic tumor volume is an adverse prognostic factor in head-and-neck cancer. Biomarkers such as MTV are important for risk stratification and will be valuable in the future with risk-adapted therapies.</abstract><cop>New York, NY</cop><pub>Elsevier Inc</pub><pmid>20646870</pmid><doi>10.1016/j.ijrobp.2010.01.057</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0360-3016 |
| ispartof | International journal of radiation oncology, biology, physics, 2011-06, Vol.80 (2), p.514-521 |
| issn | 0360-3016 1879-355X |
| language | eng |
| recordid | cdi_osti_scitechconnect_21491773 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Adolescent Adult Aged Aged, 80 and over ANTIMETABOLITES BETA DECAY RADIOISOTOPES BETA-PLUS DECAY RADIOISOTOPES Biological and medical sciences BODY Carcinoma, Squamous Cell - diagnostic imaging Carcinoma, Squamous Cell - drug therapy Carcinoma, Squamous Cell - metabolism Carcinoma, Squamous Cell - radiotherapy CARCINOMAS Combined Modality Therapy - methods COMBINED THERAPY COMPUTERIZED TOMOGRAPHY DIAGNOSTIC TECHNIQUES Disease-Free Survival DISEASES DRUGS EMISSION COMPUTED TOMOGRAPHY Female FLUORINE 18 FLUORINE ISOTOPES FLUORODEOXYGLUCOSE Fluorodeoxyglucose F18 - pharmacokinetics HEAD Head and Neck Neoplasms - diagnostic imaging Head and Neck Neoplasms - drug therapy Head and Neck Neoplasms - metabolism Head and Neck Neoplasms - radiotherapy Head-and-neck cancer Hematology, Oncology and Palliative Medicine HOURS LIVING RADIOISOTOPES Humans ISOMERIC TRANSITION ISOTOPES ISOTOPES LIGHT NUCLEI Male Medical sciences MEDICINE Metabolic tumor volume Middle Aged NANOSECONDS LIVING RADIOISOTOPES NECK NEOPLASMS NUCLEI ODD-ODD NUCLEI Otorhinolaryngology (head neck, general aspects and miscellaneous) Otorhinolaryngology. Stomatology POSITRON COMPUTED TOMOGRAPHY Positron emission tomography Positron-Emission Tomography - methods Prognosis Proportional Hazards Models RADIOISOTOPES Radiology RADIOLOGY AND NUCLEAR MEDICINE Radiopharmaceuticals - pharmacokinetics Retrospective Studies Survival Rate THERAPY TOMOGRAPHY Tomography, X-Ray Computed - methods Treatment Outcome Tumor Burden Tumors VOLUME Young Adult |
| title | Postradiation Metabolic Tumor Volume Predicts Outcome in Head-and-Neck Cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T09%3A08%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_osti_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Postradiation%20Metabolic%20Tumor%20Volume%20Predicts%20Outcome%20in%20Head-and-Neck%20Cancer&rft.jtitle=International%20journal%20of%20radiation%20oncology,%20biology,%20physics&rft.au=Murphy,%20James%20D.,%20M.D&rft.date=2011-06-01&rft.volume=80&rft.issue=2&rft.spage=514&rft.epage=521&rft.pages=514-521&rft.issn=0360-3016&rft.eissn=1879-355X&rft.coden=IOBPD3&rft_id=info:doi/10.1016/j.ijrobp.2010.01.057&rft_dat=%3Cproquest_osti_%3E1687663122%3C/proquest_osti_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1687663122&rft_id=info:pmid/20646870&rft_els_id=S0360301610002312&rfr_iscdi=true |